Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Swiss generic and biosimilar medicines firm Sandoz (SIX: SDZ) today announced it has filed an antitrust lawsuit in the USA ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market ...

Amgen (AMGN) stock in focus as Sandoz files antitrust lawsuit alleging that the company blocked copycats from targeting its ...

Etanercept is a biologic medicine used to treat a range of disabling inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules - corrected: reference to date of product launch in Europe removed; link to "Important Safety Information" updated Company aims ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow ...